Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis

Published:2021-11-30 Issue:2 Volume:37 Page:439-448
ISSN:0884-8734
Container-title:Journal of General Internal Medicine
language:en
Short-container-title:J GEN INTERN MED

Author:

Alexander Jason T.,Staab Erin M.,Wan Wen,Franco Melissa,Knitter Alexandra,Skandari M. Reza,Bolen Shari,Maruthur Nisa M.,Huang Elbert S.,Philipson Louis H.,Winn Aaron N.,Thomas Celeste C.,Zeytinoglu Meltem,Press Valerie G.,Tung Elizabeth L.,Gunter Kathryn,Bindon Brittany,Jumani Sanjay,Laiteerapong Neda

Funder

American Diabetes Association

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11606-021-07227-0.pdf

Reference37 articles.

1. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9

2. (th) edition. Diab Res Clin Pract. 2019;157:107843.